Introduction
INTRODUCTION
The role of second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) has been highlighted by a number of recent clinical trials examining the role of "maintenance" therapy. Traditionally, patients with responsive or stable disease after four to six cycles of firstline platinum doublet chemotherapy have been monitored clinically and radiographically off therapy, with second-line chemotherapy initiated upon disease progression. Currently, three agents-docetaxel, pemetrexed, and erlotinib-are approved for this indication in the United States. With maintenance therapy, patients receive subsequent treatment immediately after completing first-line chemotherapy, either with a new agent ("switch maintenance") or with an agent given during first-line therapy ("continuation maintenance").
Across studies, maintenance chemotherapy has been associated with prolongation of progression-free survival. Some trials have also demonstrated improvement in overall survival. Clinical trials of maintenance chemotherapy have been noteworthy for widely varying rates of second-line chemotherapy administration.
Among patients randomized to observation after completion of first-line treatment, anywhere from 17-82% of patients received second-line therapy upon disease progression; 3-63% of patients received the same agent given in the maintenance arm. These discrepancies have confounded the interpretation of study results. It is not clear if maintenance chemotherapy provides a benefit because of its timing, or because it exposes more patients to additional, potentially effective therapies. That is, if there were a means to predict which patients would be fit to receive second-line therapy at the time of progression, it might not be necessary to offer these individuals maintenance regimens.
Outside the controlled environment of a clinical trial, little is known about administration of second-line chemotherapy. Large administrative databases do not routinely record this information. A recently published study from South Korea reported that 86% of patients received second-line treatment. This unusually high rate exceeds those of prospective, randomized maintenance chemotherapy trials and may reflect the young age and good performance status of the patient population. Indeed, multiple lung cancer studies have demonstrated substantial differences in treatment effects and overall prognosis between East Asian and western populations.
To provide further insight into this issue, we examined the predictors and impact of second-line chemotherapy administration at a large North American medical center providing care to a diverse patient population within three different hospital systems.
METHODS

Study setting
The study cohort was captured from clinical facilities associated with the University of Texas Southwestern Medical Center (UT 
Data extraction
Recording and Definition of Variables
For each patient, the following demographic data were recorded: age, gender, race/ethnicity, and insurance type. Race/ethnicity was categorized as white (non-Hispanic), Hispanic, African-American, or other. Insurance type was recorded as one of the following: no insurance, Medicaid (a federal/state health care program for low-income families), Medicare (a federal health care program for individuals age 65 years and older), VA, and private. The designation "no insurance" primarily includes individuals ultimately treated through a Dallas
County public health plan that provides patients access to all standard diagnostic and treatment modalities. Disease variables recorded included tumor histology, date of diagnosis, and date of death or last known follow-up. Histology was categorized as adenocarcinoma, squamous cell carcinoma, or other. Overall survival was defined as the interval between date of diagnosis and date of death.
We recorded the following treatment variables: receipt of palliative radiotherapy prior to initiation of first-line chemotherapy (and site irradiated), number of cycles of first-line chemotherapy, disease status at end of first-line chemotherapy, and receipt of second-line chemotherapy. For patients who received at least four cycles of first-line chemotherapy, post-treatment disease status was characterized as progressive or non-progressive according to the overall radiographic and clinical impression in the medical record. We did not review imaging studies or employ formal scales, such as those of the World Health Organization (WHO) or Response Evaluation Criteria in Solid Tumors (RECIST) for this determination.
Statistical analysis
Descriptive statistics (medians/means for continuous variables and percentages for discrete variables) were generated for baseline demographic and clinical characteristics. Both univariate and multivariate logistic regression models were used to explore the association between demographic, disease, treatment characteristics, and receipt of second-line chemotherapy. In these analyses, age was dichotomized as < 65 years and ≥ 65 years; year of diagnosis was dichotomized as 2000-2003 and 2004-2007 ; race/ethnicity was characterized as white (non-Hispanic) or other. In the multivariate model, we included age, gender, race/ethnicity, insurance type, number of cycles of first-line chemotherapy, and pre-chemotherapy palliative radiation therapy. We analyzed the association between demographic, disease and treatment characteristics, receipt of second-line chemotherapy, and overall survival using univariate and multivariate Cox regression. Age, gender, race/ethnicity, insurance type, number of cycles of first-line chemotherapy, pre-chemotherapy palliative radiation therapy, and administration of second-line chemotherapy were included in the multivariate model. All reported P values are two-sided.
All statistical analyses were performed using SAS 9.2 Service Pack 4 for Windows (SAS Institute Inc., Cary, NC).
RESULTS
Study population
From the tumor registries, we identified a total of 472 patients who received first-line chemotherapy. Of these patients, 66 received singleagent first-line therapy (39 received a cytotoxic agent; 27 received an epidermal growth factor receptor [EGFR] tyrosine kinase inhibitor) and were excluded from the analysis. Within the remaining cohort of 406 patients, 186 (46%) were from Parkland Health and Hospital System, 153 (38%) were from the Dallas VA, and 67 (16%) were from University Hospital. Mean age was 59 years, 28% were women, and 59% were white. Additional patient characteristics are listed in Table 1 . Median follow-up was 9.4months. Of the 132 patients listed as "other" histology, 3had large cell and 129 had NSCLC not otherwise specified. Among the 121 patients who received pre-chemotherapy palliative radiation therapy, the following sites were irradiated: brain (65 patients), lung (23 patients), bone (18 patients), brain and lung (9 patients), brain and bone (5 patients), lung and bone (1 patient).
Second-line therapy administration
In univariate analysis, insurance type, number of cycles of first-line chemotherapy, and pre-chemotherapy palliative radiation therapy were significantly associated with receipt of second-line chemotherapy (see Table 2 ). number of cycles of first-line chemotherapy, and receipt of second-line chemotherapy were associated with overall survival (see Table 3 and 
FIGURE 1
Overall survival curves of patients categorized by number of cycles of first-line chemotherapy (Fig. 1a) , receipt of second-line chemotherapy (Fig. 1b) , and both the number of cycles of first-line chemotherapy and receipt of second-line chemotherapy ( 
DISCUSSION
The recent wave of clinical trials examining the role of maintenance chemotherapy for advanced NSCLC hasagain placed a spotlight on the benefits of second-line chemotherapy for this disease. Somewhat unexpectedly, these studies have revealed widely varying rates of secondline chemotherapy administration. In some studies, the likelihood of patients randomized to observation after first-line chemotherapy receiving chemotherapy at the time of progression is below 20%, raising the possibility that broader use of second-line therapies could mitigate some of the benefit attributed to a maintenance approach. The study of immediate (i.e., maintenance) or delayed docetaxel following 4 cycles of first-line therapy provides a prime example of this scenario; overall survival for patients who received immediate docetaxel and for the two-thirds of patients randomized to delayed docetaxel who ultimately received the assigned treatment was identical.
The current study, which employs a contemporary, diverse, and unselected population, offers further insight into the real-world experience of second-line NSCLC treatment. In this cohort, 67% of individuals who had not progressed after receiving 4 cycles of first-line chemotherapy countries, throughout which second-line practice patterns could vary considerably-left the administration and selection of post-progression treatment to the discretion of the investigator rather than mandating second-line therapy for patients in the non-maintenance arm. A third study included a high proportion of patients with poor performance status(>80% ECOG 2).
We found the following variables to be associated with receipt of second-line chemotherapy: insurance type, number of cycles of first-line chemotherapy, and receipt of palliative radiation therapy prior to first-line chemotherapy administration. In a previous study of a similar patient cohort, we found that older patients with advanced NSCLC were less likely to receive first-line chemotherapy, presumably because older individuals tend to be more frail and have more medical comorbidities. It seems logical that age would not be associated with receipt of second-line chemotherapy in the same population because those older patients not fit for chemotherapy have already been selected out of the present study cohort. These observations echo those of a subset analysis of the phase III trial of second-line pemetrexed versus docetaxel, in which elderly patient participation was similar to rates observed in the first-line setting. By contrast, we found insurance type to predict receipt of both first-line and second-line treatment. While reasons for this ongoing association throughout the entire disease course are not evident from either study, it seems possible that insurance type-a surrogate marker of socioeconomic status-could be associated not only with performance status and comorbidities, but also with treatment preferences and adherence to medical care, factors that continue to impact populations well beyond first-line chemotherapy. Year of diagnosis was not associated with second-line chemotherapy administration, although we had expected to see an increase after 2004, when results of phase III trials of second-line erlotinib and pemetrexed, as well as second-line docetaxel quality of life data, were presented. Our use of pre-chemotherapy palliative radiation therapy as a predictive variable also merits comment. We selected this unconventional metric as a potential marker of disease burden and severity. It represents a diverse group of patients, including those with brain metastases; clinically significant hemoptysis or airway compromise; and refractory pain, neurologic sequelae, or skeletal instability from bony metastases. It is possible that these patients represent a population at subsequent risk for a more symptomatic, complex clinical course. It follows that these patients are substantially less likely to receive second-line chemotherapy (OR 0.53 in this study). It seems less likely that pre-chemotherapy palliative radiation therapy itself-either via the delay in initiation of systemic therapy or through radiation-associated toxicities-accounts for the reduced rate of second-line chemotherapy administration.
Both the number of cycles of first-line chemotherapy and the receipt of second-line chemotherapy were independently associated with overall survival. While no conclusions about the effect of these treatment factors on clinical endpoints can be drawn from this observational, non-randomized trial, these findings may provide insight into overall outcomes. We selected a cut-off of 4 cycles of first-line chemotherapy because this number implies clinical effect (as radiographic studies assessing response to therapy are typically performed every 2 cycles), acceptable toxicity profile, and patient adherence to treatment. Among patients who ultimately received second-line chemotherapy, median survival was 17.9 months for those who received 4 or more cycles of first-line chemotherapy, compared to 8.7 months for those who received fewer than 4 cycles of first-line chemotherapy. These findings echo those of earlier studies, in which response to first-line chemotherapy was an independent predictor of receipt of second-line chemotherapy and overall survival.
Limitations of this study include its retrospective nature, its single academic center setting, and relatively small sample size. Despite the retrospective design, disease and treatment follow-up data were available until patient death for over 95% of the cohort. Due to the geographical setting and variety of UT Southwestern-affiliated clinical facilities, our patient cohort is racially and socioeconomically diverse.
Nonetheless, certain patient populations, such as East Asians, are under-represented. Furthermore, the physicians caring for these individuals are predominantly academic thoracic oncologists, who may be more likely to employ second-line chemotherapy than are other practitioners.
That stated, the ability of these physicians to deliver second-line chemotherapy to two-thirds of this largely socioeconomically challenged cohort suggests that it may be feasible in most other U.S. settings as well. Finally, reasons why second-line chemotherapy was not administered were not available.
In conclusion, in this unselected, diverse cohort of patients with advanced NSCLC, approximately 50% of patients who received first-line chemotherapy eventually received second-line chemotherapy. Limiting the analysis to those individuals whose disease did not progress after 4-6 cycles of first-line chemotherapy-the population eligible for maintenance chemotherapy-the rate rises to 67%, a figure that meets or exceeds those of numerous recent clinical trials. Markers of socioeconomic status, symptom burden, and response to and tolerance of firstline chemotherapy were associated with receipt of second-line chemotherapy. Maintenance chemotherapy trials have highlighted critical economic and quality of life issues. The cost per life-year gained from maintenance pemetrexed exceeds $120,000. While approved maintenance agents such as pemetrexed and erlotinib are generally well tolerated, there is clearly a subset of patients who maintain prolonged disease control after first-line chemotherapy with no subsequent treatment-and who then successfully receive second-line therapy at the time of progression. It follows that identifying those patients least likely to receive second-line chemotherapy might guide the selective use of maintenance chemotherapy, thereby limiting both costs and toxicities. Based on the findings in the present study, socioeconomically disadvantaged patients and patients with greater symptom burden-manifest by the need for pre-chemotherapy palliative radiation therapy-may represent such a target population. 
